Drug Type Biosimilar, Monoclonal antibody |
Synonyms Omalizumab biosimilar, 奥马佐单抗生物类似药 (中央研究院), FB-317 |
Target |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Allergic asthma | Phase 1 | TW | 30 Jan 2022 | |
Chronic Urticaria | Phase 1 | TW | 30 Jan 2022 | |
Asthma | Phase 1 | - | - | |
Asthma | Phase 1 | - | - | |
Urticaria | Phase 1 | - | - | |
Urticaria | Phase 1 | - | - |